Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.98 +0.6%	$24.67	$22.64 ▼ $53.96	$1.22B	0.77	489,255 shs	365,928 shs
ARCT Arcturus Therapeutics	$12.87 +4.0%	$11.76	$8.04 ▼ $30.39	$349.05M	2.3	438,544 shs	436,301 shs
BGM Qilian International Holding Group	$14.10 +4.4%	$12.11	$5.26 ▼ $17.17	$1.37B	1.38	30,448 shs	111,797 shs
TVTX Travere Therapeutics	$14.68 +1.2%	$16.87	$6.80 ▼ $25.29	$1.30B	0.75	1.62 million shs	1.66 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	-0.65%	+3.86%	-6.75%	-36.23%
ARCT Arcturus Therapeutics	0.00%	-3.21%	+6.27%	-12.57%	-60.06%
BGM Qilian International Holding Group	0.00%	+3.21%	+7.66%	+34.60%	+1,349,999,900.00%
TVTX Travere Therapeutics	0.00%	-5.35%	-13.69%	-30.52%	+102.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	3.762 of 5 stars	2.1	1.0	0.0	3.7	2.9	4.2	1.3
ARCT Arcturus Therapeutics	3.242 of 5 stars	4.6	0.0	0.0	0.0	3.5	2.5	0.6
BGM Qilian International Holding Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	2.4866 of 5 stars	4.4	1.0	0.0	0.0	1.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	24.45% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	315.70% Upside
BGM Qilian International Holding Group	0.00	N/A	N/A	N/A
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	118.96% Upside

Current Analyst Ratings Breakdown

Latest ARCT, TVTX, BGM, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/16/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$730.66M	1.68	$3.62 per share	7.17	$13.35 per share	1.95
ARCT Arcturus Therapeutics	$131.27M	2.66	N/A	N/A	$10.42 per share	1.24
BGM Qilian International Holding Group	$25.10M	54.62	N/A	N/A	$6.10 per share	2.31
TVTX Travere Therapeutics	$273.53M	4.77	N/A	N/A	$2.67 per share	5.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$2.76	8.66	7.90	2.19	21.80%	26.44%	11.89%	8/6/2025 (Estimated)
ARCT Arcturus Therapeutics	-$29.73M	-$2.53	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	8/4/2025 (Estimated)
BGM Qilian International Holding Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	-$111.40M	-$2.81	N/A	N/A	N/A	-137.90%	-1,636.87%	-55.95%	7/30/2025 (Estimated)

Latest ARCT, TVTX, BGM, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	5.56%	N/A	N/A	N/A
BGM Qilian International Holding Group	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
ARCT Arcturus Therapeutics	N/A	4.76	4.76
BGM Qilian International Holding Group	N/A	3.39	2.82
TVTX Travere Therapeutics	24.96	1.71	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ARCT Arcturus Therapeutics	94.54%
BGM Qilian International Holding Group	N/A
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
ARCT Arcturus Therapeutics	16.60%
BGM Qilian International Holding Group	58.66%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.14 million	35.05 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
BGM Qilian International Holding Group	298	97.22 million	2.48 million	N/A
TVTX Travere Therapeutics	460	88.81 million	75.12 million	Optionable

ARCT, TVTX, BGM, and AMPH Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 16 at 3:15 PM | accessnewswire.com

Equities Analysts Set Expectations for TVTX FY2025 Earnings

June 16 at 1:35 AM | marketbeat.com

What is HC Wainwright's Estimate for TVTX Q2 Earnings?

June 16 at 1:20 AM | marketbeat.com

Travere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdles

June 15 at 2:42 PM | investing.com

Assenagon Asset Management S.A. Sells 116,999 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

June 15 at 4:25 AM | marketbeat.com

Leerink Partnrs Has Bearish Forecast for TVTX Q4 Earnings

June 15 at 1:59 AM | americanbankingnews.com

HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs

June 14 at 8:20 PM | finance.yahoo.com

HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs

June 13 at 3:50 PM | insidermonkey.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 13 at 10:00 AM | accessnewswire.com

Q4 EPS Estimate for Travere Therapeutics Lowered by Analyst

June 13 at 6:07 AM | marketbeat.com

Cantor Fitzgerald Comments on TVTX FY2026 Earnings

June 13 at 2:57 AM | americanbankingnews.com

Travere Therapeutics (NASDAQ:TVTX) Price Target Lowered to $32.00 at Citigroup

June 13 at 1:55 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 12, 2025 | prnewswire.com

Travere Therapeutics (NASDAQ:TVTX) Now Covered by Analysts at HC Wainwright

June 12, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 11, 2025 | accessnewswire.com

Cantor Fitzgerald Predicts TVTX FY2026 Earnings

June 11, 2025 | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Given "Buy" Rating at HC Wainwright

June 11, 2025 | marketbeat.com

Citigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price

June 11, 2025 | marketbeat.com

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

June 11, 2025 | businesswire.com

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

June 10, 2025 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 9, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, TVTX, BGM, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.98 +0.16 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$25.98 0.00 (-0.02%)

As of 07:17 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Arcturus Therapeutics NASDAQ:ARCT

$12.87 +0.49 (+3.96%)

Closing price 04:00 PM Eastern

Extended Trading

$13.10 +0.24 (+1.83%)

As of 06:49 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Qilian International Holding Group NASDAQ:BGM

$14.10 +0.60 (+4.44%)

Closing price 03:59 PM Eastern

Extended Trading

$14.74 +0.65 (+4.57%)

As of 05:53 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Travere Therapeutics NASDAQ:TVTX

$14.68 +0.18 (+1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$14.94 +0.26 (+1.77%)

As of 06:32 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time